ANGO Key Statistics, Chart & Performance
The current stock price of ANGO is 9.98 USD. In the past month the price decreased by -23.23%. In the past year, price decreased by -12.53%.
ANGO Technical Analysis
ANGO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ANGO. Both the profitability and financial health of ANGO have multiple concerns.
ANGO Financial Highlights
Over the last trailing twelve months ANGO reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 72.97% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.28% | ||
| ROE | -15.71% | ||
| Debt/Equity | 0.03 |
ANGO Forecast & Estimates
10 analysts have analysed ANGO and the average price target is 19.72 USD. This implies a price increase of 97.6% is expected in the next year compared to the current price of 9.98.
For the next year, analysts expect an EPS growth of -97.2% and a revenue growth 9.15% for ANGO
ANGO Ownership
About ANGO
Company Profile
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 675 full-time employees. The company went IPO on 2004-05-27. The firm is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The company designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Company Info
ANGIODYNAMICS INC
14 Plaza Drive
Latham NEW YORK 12110 US
CEO: James C. Clemmer
Employees: 675
Phone: 15187981215
ANGIODYNAMICS INC / ANGO FAQ
What does ANGO do?
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 675 full-time employees. The company went IPO on 2004-05-27. The firm is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. The company designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.
Can you provide the latest stock price for ANGIODYNAMICS INC?
The current stock price of ANGO is 9.98 USD. The price decreased by -0.3% in the last trading session.
What is the dividend status of ANGIODYNAMICS INC?
ANGO does not pay a dividend.
What is the ChartMill technical and fundamental rating of ANGO stock?
ANGO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the growth outlook for ANGIODYNAMICS INC?
The Revenue of ANGIODYNAMICS INC (ANGO) is expected to grow by 9.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for ANGO stock?
ANGIODYNAMICS INC (ANGO) currently has 675 employees.
What is the Short Interest ratio of ANGIODYNAMICS INC (ANGO) stock?
The outstanding short interest for ANGIODYNAMICS INC (ANGO) is 4.91% of its float.